A network of European centres collects European pharmacokinetic data in pregnant women. The initiator of this European network is Prof. Dr. David Burger at the Radboud University Nijmegen Medical Centre, the Netherlands. Dr. Angela Colbers is the coordinator of the PANNA study.

Why setting up a European Network?

In the US, a network performing PK studies (amongst other research) in pregnant women is in place: IMPAACT (formerly PACTG). The US population is a different patient population compared to the European population.

The EMA requires data in the European population as well: “patients entering clinical trials should be reasonably representative of the population that will be later treated by the drug”. In Europe, the demographics of HIV-infected pregnant women (Caucasian females and females born in Sub-Saharan Africa) are different from the US population.
study centres

Participate as a new study centre

To apply for participation in the study you can fill in the contact details of your centre in the application form. After your application you will be contacted for screening and you will receive further information on how to start up the PANNA study in your centre.


  • capability of doing 12h or 24h PK recordings
  • access to a research unit/clinical ward for in-house PK sampling
  • research nurse & lab facilities (handling, storage)
  • large clinical site (>40 deliveries/year)
  • having a multidisciplinary team (ID specialist, gynaecologists/obstetricians, paediatricians)

Application form

Please fill in the apllication form to receive further information to participate as a new study centre.

Study centres

As a physician you can include patients by referral to a study centre near you. Choose your country and find the nearest centre for more information.

It is also possible to participate as a study centre in the PANNA study. Are you interested in applying? Please read the requirements and apply.

Click on your country


The PANNA study is powered by: